US Edition
News from bionity.com
We’ve assigned a media bias rating of unknown to bionity.com. You can read more about our methodology here.
If you want to know if bionity.com is credible or reliable, look no further. We rank bionity.com as Unknown factuality. Find out more about our methodology here.
Media Bias Ratings
Do you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top bionity.com News
Eli LillyRepertoire Immune Medicines entered a strategic collaboration on Thursday with Eli Lilly and Co. (NYSE:LLY) to develop tolerizing therapies for multiple autoimmune diseases. • Eli Lilly and Co stock is showing positive momentum. Where are LLY shares going? Repertoire Immune is a biotechnology company focused on the discovery and development of programmable T cell-targeted immune medicines. Under the terms of the agreement, Repertoire will receiv…See the Story
Eli Lilly Teams Up With Two Biotechs To Target Autoimmune Disease, Hearing Loss In Deals Worth $3 Billion - Eli Lilly and Co (NYSE:LLY)
87% Center coverage: 8 sources
